Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Recruiting now · Phase 3

Conditions studied: Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis

In brief

To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients received radiotherapy.

Key facts

Study ID

NCT07311772

Run by

Sun Yat-sen University

People needed

386

Starts

2025-12-16

Expected to finish

2027-08-15

Last updated by the study team

2026-05-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC);
• Age: 18 to 75 years old;
• Karnofsky Performance Status (KPS) score ≥ 80 before treatment;
• No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy;
• Requiring radical radiotherapy;
• The patient has signed the informed consent form and is willing and able to comply with the study's follow-up visits, treatment plan, laboratory tests, and other research procedures.

You may not qualify if…

• Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments;
• Previous history of head and neck radiotherapy;
• Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs);
• Local use of Houyanqing Oral Liquid, Recombinant Human Epidermal Growth Factor (rhEGF) Topical Solution, Vitamin B12 Solution, or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) mouthwash in the oral cavity within one month before enrollment;
• Comorbidities requiring long-term treatment with immunosuppressive drugs, or systemic/local use of corticosteroids at immunosuppressive doses before enrollment;
• HIV-positive patients;
• Pregnant women or lactating women;
• Patients with severe mental illnesses;
• Patients with severe cardio-cerebrovascular diseases, endocrine disorders, infectious diseases, or other tumors.

Where it is running

• Cancer Hospital Chinese Academy of Medical Science — Beijing, Beijing Municipality, China (enrolling)
• Fujian Medical University Cancer Hospital — Fuzhou, Fujian, China (enrolling)
• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)
• Affiliated Cancer Hospital & Institute of Guangzhou Medical University — Guangzhou, Guangdong, China (enrolling)
• Cancer Hospital of Shantou University Medical College — Shantou, Guangdong, China (enrolling)
• Fifth Affiliated Hospital of Sun Yat-sen University — Zhuhai, Guangdong, China (enrolling)
• Cancer Hospital of Guangxi Medical University — Nanning, Guangxi, China (enrolling)
• Wuzhou Red Cross Hospital — Wuzhou, Guangxi, China (enrolling)
• Xiangya Hospital of Central South University — Changsha, Hunan, China (enrolling)
• Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)
• The First People's Hospital of Changzhou — Changzhou, Jiangsu, China (enrolling)
• Eye & ENT Hospital of Fudan University — Shanghai, Shanghai Municipality, China (enrolling)
• West China Hospital of Sichuan University — Chengdu, Sichuan, China (enrolling)
• The First Affiliated Hospital of Kunming Medical University — Kunming, Yunnan, China (enrolling)
• Yunnan Cancer Hospital — Kunming, Yunnan, China (enrolling)
• Zhejiang Cancer Hospital — Hangzhou, Zhengjiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.